Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- Chuikyo Wants to Stick to 14-Day Prescription Limit
November 9, 2015
- Generic Brand-Specified Prescriptions Not Permitting Substitution Decline to 15.9%: FY2015 Survey
November 9, 2015
- Editor’s Pick: Five Healthcare Policy News Headlines for October
November 6, 2015
- 4 PMDA Advisors to Resign over Conflicts of Interest
November 6, 2015
- AMED Now Taking Applications for Pre-Orphan Designation Scheme
November 6, 2015
- Chuikyo Payer Rep Urges Further Price Cuts for Long-Listed Products with Low Generic Rates
November 5, 2015
- Chuikyo Doctor Reps Positive, but Payers Wary about Industry’s Ideas on “Essential Drugs”
November 5, 2015
- AMED Aims to Give Society Access to Results of Research in Genomic Medicine: President
November 5, 2015
- Pricing Rule for Essential Drugs Top Priority in FY2016 Reform: Ex-MHLW Economic Affairs Head
November 4, 2015
- PMDA Reviewing Opdivo for Risk of Type 1 Diabetes
November 4, 2015
- PAFSC 1st Committee Recommends Approval for Social Anxiety Disorder for Lexapro
November 4, 2015
- MHLW Weighs Another Business Improvement Order to Novartis
November 4, 2015
- Fiscal System Council Approves MOF’s Proposal for NHI Pricing System Reform
November 2, 2015
- MOF Proposes Full Implementation of Cost-Effective Assessments as Precondition for Full-Scale Introduction of Premium for New Drug Development
November 2, 2015
- Takeda’s Hib Vaccine to Be Reported to PAC in December
November 2, 2015
- PAFSC’s 2nd Committee Receives Report on Add’l Indication for Xeloda, Elplat
November 2, 2015
- MOF Asks Fiscal System Council to Issue Conclusion on Market Price Survey for FY2017 Revision “by Mid-2016 at Latest”
November 2, 2015
- 30% of Generic Companies Unable to Prepare Stable Supply Manuals by End of FY2014; MHLW Official Calls for Early Preparation
October 30, 2015
- Chuikyo Agrees to Tweak “Cost per Course of Treatment” Rule for Combo Drugs after Harvoni Debate
October 29, 2015
- Chuikyo Subcommittee Discusses Envisaged HTA Organization
October 29, 2015
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…